LT3628049T - Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai - Google Patents

Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai

Info

Publication number
LT3628049T
LT3628049T LTEPPCT/US2018/030816T LT18030816T LT3628049T LT 3628049 T LT3628049 T LT 3628049T LT 18030816 T LT18030816 T LT 18030816T LT 3628049 T LT3628049 T LT 3628049T
Authority
LT
Lithuania
Prior art keywords
tgf
fusion proteins
receptor type
beta receptor
beta
Prior art date
Application number
LTEPPCT/US2018/030816T
Other languages
English (en)
Inventor
Ravindra Kumar
Dianne S. Sako
Original Assignee
Acceleron Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc. filed Critical Acceleron Pharma Inc.
Publication of LT3628049T publication Critical patent/LT3628049T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEPPCT/US2018/030816T 2017-05-04 2018-05-03 Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai LT3628049T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762501229P 2017-05-04 2017-05-04
US201762510422P 2017-05-24 2017-05-24
US201762578674P 2017-10-30 2017-10-30
PCT/US2018/030816 WO2018204594A1 (en) 2017-05-04 2018-05-03 Tgf-beta receptor type ii fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
LT3628049T true LT3628049T (lt) 2023-08-25

Family

ID=64016255

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/030816T LT3628049T (lt) 2017-05-04 2018-05-03 Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai

Country Status (21)

Country Link
US (2) US11021527B2 (lt)
EP (2) EP3628049B1 (lt)
JP (2) JP7267664B2 (lt)
KR (2) KR20240023201A (lt)
CN (1) CN110785431B (lt)
AU (2) AU2018261131A1 (lt)
BR (1) BR112019023071A2 (lt)
CA (1) CA3061472A1 (lt)
CY (1) CY1126121T1 (lt)
DK (1) DK3628049T3 (lt)
ES (1) ES2948647T3 (lt)
FI (1) FI3628049T3 (lt)
HR (1) HRP20230706T1 (lt)
HU (1) HUE063840T2 (lt)
LT (1) LT3628049T (lt)
MD (1) MD3628049T2 (lt)
PL (1) PL3628049T3 (lt)
PT (1) PT3628049T (lt)
RS (1) RS64315B1 (lt)
SI (1) SI3628049T1 (lt)
WO (1) WO2018204594A1 (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
JP7320350B2 (ja) 2015-08-04 2023-08-03 アクセルロン ファーマ インコーポレイテッド 骨髄増殖性障害を処置するための方法
RU2021114098A (ru) 2016-07-15 2021-12-14 Акселерон Фарма Инк. Композиции и способы для лечения легочной гипертензии
MX2019010392A (es) 2017-03-02 2019-12-02 Nat Res Council Canada Moleculas de fusion de ectodominios receptores de tgf-b y sus usos.
BR112020025804A2 (pt) 2018-06-22 2021-03-23 Kite Pharma, Inc. proteínas transmembranares quiméricas e usos das mesmas
EP3820496A4 (en) 2018-07-09 2022-04-20 Precigen, Inc. FUSION CONSTRUCTS AND METHODS OF USE THEREOF
KR20220044833A (ko) * 2019-08-15 2022-04-11 난트바이오 인코포레이티드 Tgf-베타 트랩
CN110734498A (zh) * 2019-10-15 2020-01-31 上海科棋药业科技有限公司 一种用于解除免疫抑制的融合蛋白及其应用
BR122023021925A2 (pt) 2019-10-23 2024-02-27 Cue Biopharma, Inc Complexo de tgf-b, seus usos, um ou mais ácidos nucleicos, composição, método para produzir uma construção ou complexo de tgf-b mascarado, composição farmacêutica, método para entrega de um polipeptídeo tgf-b e opcionalmente pelo menos um polipeptídeo mod a células que expressam em sua membrana superficial um tbr
MX2022005491A (es) * 2019-11-05 2022-07-27 Acceleron Pharma Inc Tratamientos contra esclerosis sistémica.
WO2021218883A1 (zh) * 2020-04-28 2021-11-04 神州细胞工程有限公司 一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途
CA3174130A1 (en) * 2020-11-23 2022-05-27 Cue Biopharma, Inc. Tgf-beta polypeptides
EP4351723A2 (en) * 2021-06-11 2024-04-17 Acceleron Pharma Inc. Actrii proteins and uses thereof

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
ZA914750B (en) 1990-06-20 1992-03-25 Bristol Myers Squibb Co Methods of modulating blood pressure using tgf-beta and antagonists thereof
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
JP4124815B2 (ja) 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
US5543143A (en) 1992-03-06 1996-08-06 Corixa Corporation Method for activating macrophages/monocytes
ES2174868T3 (es) 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
DE69434934D1 (de) 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5866323A (en) 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US6423501B2 (en) 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
BR9808934A (pt) 1997-04-18 2000-08-01 Biogen Inc Proteìnas de fusão de região constante de receptor/imunoglobulina tgf-beta do tipo ii
AU7467898A (en) 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
CA2330939A1 (en) 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
IL151369A0 (en) 2000-03-09 2003-04-10 Genzyme Corp USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION
US20040234967A1 (en) 2000-03-24 2004-11-25 Moskowitz David W. Diagnostic polymorphisms of tgf-beta-rii promoter
US20030028905A1 (en) 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
US20030180301A1 (en) 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CA2513086A1 (en) 2002-12-19 2004-07-08 Scios Inc. Treatment of obesity and associated conditions with tgf-.beta. inhibitors
WO2004098637A1 (en) 2003-04-30 2004-11-18 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2007502284A (ja) 2003-08-13 2007-02-08 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ｓｉＲＮＡによるＴＧＦベータＩＩ型受容体発現のサイレンシング
CN1838958A (zh) 2003-08-22 2006-09-27 贝林格尔·英格海姆药物公司 治疗慢性阻塞性肺病和肺动脉高血压的方法
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US7786261B2 (en) 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
US7867496B2 (en) 2004-09-22 2011-01-11 Genzyme Corporation Use of TGF-β antagonists to limit nephrotoxicity of immunosuppressive agents
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
JP5481028B2 (ja) 2004-10-13 2014-04-23 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連リンパ増殖性障害を処置または予防するための方法
CN104151427B (zh) 2005-02-08 2017-09-08 根茨美公司 针对TGFβ的抗体
JP5342834B2 (ja) 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
ITMI20060181A1 (it) 2006-02-03 2007-08-04 Univ Padova Modulatori del tgf-b e loro uso
EP2230252A1 (en) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP2029625A2 (en) 2006-06-05 2009-03-04 Novartis AG Use of tgf-beta antagonists in treatment of parathyroid-related disorders
DK2918288T3 (da) 2006-10-03 2017-11-27 Genzyme Corp Anvendelse af TGF-beta-antagonister til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
EP2140005B1 (en) 2007-03-19 2013-12-11 National Research Council of Canada Fusion proteins comprising two tgf-beta binding domains
EP2171062A1 (en) 2007-06-15 2010-04-07 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
BRPI0815572A2 (pt) 2007-08-22 2015-02-18 Irm Llc Compostos e composições como inibidores de quinases
JP2011509676A (ja) 2008-01-18 2011-03-31 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ヒトＴｈ１７細胞の選択的分化、同定および調節
WO2009143309A2 (en) 2008-05-21 2009-11-26 Trustees Of Dartmouth College Female reproductive tract and anal prophylaxes
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
EP2326670A4 (en) 2008-09-17 2014-04-16 Nat Res Council Canada HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
US20120010178A1 (en) 2008-10-21 2012-01-12 President And Fellows Of Harvard College Methods and compounds for treatment of neurodegenerative disorders
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
WO2010129515A1 (en) 2009-05-08 2010-11-11 The United Satates Of America As Represented By The Secretary, Department Of Health & Human Services Modulation of the tgf-beta and pi3k/akt pathways in the diagnosis and treatment of squamous cell carcinoma
EP2524038A4 (en) 2010-01-12 2013-11-20 Isis Pharmaceuticals Inc MODULATION OF TRANSFORMING A GROWTH FACTOR BETA-1 EXPRESSION
EP3798237A1 (en) 2010-03-05 2021-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CN101852804B (zh) 2010-03-29 2013-06-12 中国医学科学院病原生物学研究所 Gdf15蛋白的抗体的新用途
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
RU2637088C2 (ru) 2010-09-01 2017-11-29 Джензим Корпорейшн Лечение инфаркта миокарда с использованием антагонистов tgf-бета
US20130287688A1 (en) 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
US8800906B2 (en) 2010-12-27 2014-08-12 The Board Of Trustees Of The Leland Stanford Junior University Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain
CA2823104A1 (en) 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
KR101517320B1 (ko) * 2011-04-19 2015-05-28 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
CA2833747C (en) 2011-04-20 2022-10-18 Asya Grinberg Endoglin polypeptides and uses thereof
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
US9468666B2 (en) 2011-08-01 2016-10-18 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
WO2013059879A1 (en) 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
CN104334573A (zh) 2012-04-30 2015-02-04 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
WO2013173307A1 (en) 2012-05-16 2013-11-21 Neil Desai Multi-target modulation for treating fibrosis and inflammatory conditions
KR102258457B1 (ko) 2013-03-11 2021-05-31 젠자임 코포레이션 조작된 항-tgf-베타 항체 및 항원-결합 단편
ES2704411T3 (es) 2013-03-12 2019-03-18 Biocon Ltd Proteínas de fusión inmunomoduladoras y procedimientos de fabricación de las mismas
US10584158B2 (en) 2013-04-17 2020-03-10 Baylor College Of Medicine Immunosuppressive TGF-β signal converter
AU2014308751B2 (en) * 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
WO2015077540A2 (en) 2013-11-21 2015-05-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
BR112016014952A2 (pt) * 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
WO2015179227A1 (en) 2014-05-18 2015-11-26 Children's Medical Center Corporation Methods and compositions relating to exosomes
EP3154559B1 (en) 2014-06-13 2021-09-01 Novartis AG Use of serelaxin to reduce gdf-15
WO2016019368A1 (en) 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
JP6631865B2 (ja) * 2014-08-11 2020-01-15 日本化薬株式会社 ＴＧＦβ阻害機能を持つキメラタンパク質
EA202190016A1 (ru) 2015-04-06 2021-08-31 Акселерон Фарма Инк. Гетеромультимеры рецепторов типа i и типа ii белков суперсемейства tgf-бета
LT3280727T (lt) 2015-04-06 2021-04-12 Acceleron Pharma Inc. Vienos atšakos i tipo ir ii tipo receptorių sulieti baltymai ir jų naudojimas
JP7320350B2 (ja) 2015-08-04 2023-08-03 アクセルロン ファーマ インコーポレイテッド 骨髄増殖性障害を処置するための方法
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
WO2017134592A1 (en) 2016-02-03 2017-08-10 Biocon Limited Anti-cd20/immunomodulatory fusion proteins and methods for making same
SG11201901126UA (en) 2016-08-12 2019-03-28 Merck Patent Gmbh Combination therapy for cancer
EP3519442A4 (en) * 2016-09-27 2020-06-17 EpicentRx, Inc. IMMUNOMODULATORY FUSION PROTEINS
JP2020514290A (ja) 2017-01-07 2020-05-21 メルク パテント ゲーエムベーハー 標的ｔｇｆ−β阻害のための投薬計画及び投薬形態
MX2019010392A (es) 2017-03-02 2019-12-02 Nat Res Council Canada Moleculas de fusion de ectodominios receptores de tgf-b y sus usos.
US20220211805A1 (en) 2018-02-09 2022-07-07 Acceleron Pharma Inc. Methods for treating heterotopic ossification

Also Published As

Publication number Publication date
SI3628049T1 (sl) 2023-10-30
BR112019023071A2 (pt) 2020-06-09
CN110785431A (zh) 2020-02-11
FI3628049T3 (fi) 2023-07-26
KR20200003873A (ko) 2020-01-10
EP3628049B1 (en) 2023-05-10
CY1126121T1 (el) 2023-11-15
DK3628049T3 (da) 2023-08-14
CA3061472A1 (en) 2018-11-08
EP3628049A1 (en) 2020-04-01
JP2023055827A (ja) 2023-04-18
US11021527B2 (en) 2021-06-01
EP4241848A2 (en) 2023-09-13
PT3628049T (pt) 2023-07-03
MD3628049T2 (ro) 2023-10-31
JP2020518246A (ja) 2020-06-25
HUE063840T2 (hu) 2024-02-28
EP3628049A4 (en) 2021-01-13
KR20240023201A (ko) 2024-02-20
KR102635723B1 (ko) 2024-02-08
RS64315B1 (sr) 2023-08-31
US20180327477A1 (en) 2018-11-15
EP4241848A3 (en) 2023-11-01
AU2018261131A1 (en) 2019-11-07
ES2948647T3 (es) 2023-09-15
AU2023200218A1 (en) 2023-02-16
WO2018204594A1 (en) 2018-11-08
US20210324040A1 (en) 2021-10-21
HRP20230706T1 (hr) 2023-10-13
PL3628049T3 (pl) 2023-09-25
JP7267664B2 (ja) 2023-05-02
CN110785431B (zh) 2024-05-07

Similar Documents

Publication Publication Date Title
LT3628049T (lt) Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
HK1246317A1 (zh) 免疫調節融合蛋白及其用途
HK1250044A1 (zh) Gitrl融合蛋白及其用途
HK1252958A1 (zh) 單臂i型和ii型受體融合蛋白和其用途
ZA201808284B (en) Gdf15 fusion proteins and uses thereof
IL265657A (en) Immunomodulatory fusion proteins
EP3287470A4 (en) Novel recombinant bi-functional fusion protein and preparation and application therefor
EP3122783A4 (en) Novel recombinant bi-functional fusion proteins, preparation and use thereof
GB2570063B (en) Fusion protein and applications thereof
IL297395B1 (en) btla fusion protein agonists and uses thereof
EP3722305A4 (en) HM-3 FUSION PROTEIN AND USES THEREOF
EP3668551A4 (en) APOM FC FUSION PROTEINS AND USES THEREOF
ZA202003845B (en) Fusion proteins
IL273626A (en) Immunomodulatory fusion proteins
GB201602850D0 (en) Fusion proteins
EP3649159C0 (en) FUSION PROTEIN
GB201712792D0 (en) Fusion protein
EP3517542A4 (en) PEPTIDE TARGETING DENDRITIC CELLS, FUSION PEPTIDE USING THE SAME, AND VACCINE USING THE SAME
HK1251456A1 (zh) 免疫球蛋白融合蛋白及其用途
MA48863A (fr) Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées